主题评价:
  • 0 次(票) - 平均星级: 0
  • 1
  • 2
  • 3
  • 4
  • 5
further strengthening our pipeline and widening
#1
battling cancer has not only been a health issue, but a considerable financial burden brought on http://poligonoindustrial.sanisidro.es/f...en-resept/ by cancer treatment. Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We sincerely hope our trastuzumab biosimilar will https://metin2corundum.ro/board/viewtopi...=9&t=24720
do exactly that,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by
回复


论坛跳转:


正在浏览该主题的用户: 1 个游客